MedDRA preferred term

Social avoidant behaviour: adverse event reports recording this term

5,698 reports to FDA record it, 2004–2026; 0% of the database.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

5,698
reports recording the term: 0% of all reports; 178
reports, 12 months to June 2026: 125 in the 12 months before; 81.3%
marked serious by the reporter: 57.4% across all reports; 5.7%
record death among outcomes, as reported: 9.1% across all reports

5,698 reports in FDA's adverse event database record the MedDRA term "Social avoidant behaviour": 0% of all reports received between January 2004 and June 2026. Coders pick the term that best matches the reporter's description.

178 reports recorded it in the 12 months to June 2026, up 42% from 125 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. Of reports recording this term, 81.3% are marked serious, 5.7% include death among the outcomes and 23.6% include hospitalisation, as reported.

The drugs listed most often as suspect products in those reports are Novothyrox, Olanzapine and Aripiprazole. That order mostly follows how many reports each drug has overall; the table also gives the term's share within each drug's own reports. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Drugs listed as suspect products in these reports

Drug	Class	Reports with this term	Share of the drug's own reports
Novothyrox	—	401	3.8%
Olanzapine	Atypical antipsychotic	185	0.4%
Aripiprazole	Atypical antipsychotic	184	0.6%
OxyContin	Opioid agonist	176	0.1%
Oxycodone hydrochloride	Opioid agonist	172	0.2%
Abilify	Atypical antipsychotic	140	0.3%
Risperidone	Atypical antipsychotic	138	0.3%
Chantix	Partial cholinergic nicotinic agonist	135	0.2%
Simvastatin	HMG-CoA reductase inhibitor	130	0.4%
Euthyrox	l-Thyroxine	124	3.4%
Seroquel	Atypical antipsychotic	122	0.2%
Singulair	Leukotriene receptor antagonist	122	0.6%
Quetiapine	Atypical antipsychotic	113	0.2%
Cymbalta	Serotonin and norepinephrine reuptake inhibitor	111	0.2%
Paxil	Serotonin reuptake inhibitor	93	0.4%
Risperdal	Atypical antipsychotic	93	0.2%
Montelukast	Leukotriene receptor antagonist	92	0.7%
Clozapine	Atypical antipsychotic	87	0.1%
Hydrocodone bitartrate and acetaminophen	Opioid agonist	83	0.1%
Sertraline	Serotonin reuptake inhibitor	81	0.2%
Vyvanse	Central nervous system stimulant	76	0.4%
Fluoxetine	Serotonin reuptake inhibitor	74	0.3%
Diazepam	Benzodiazepine	68	0.2%
Digoxin	Cardiac glycoside	64	0.4%
Abilify Maintena	—	63	0.7%

Drugs with a page on this site, ordered by the number of their reports recording this term. The last column is the term's share within that drug's own reports, against 0% across the whole database. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

By pharmacologic class

Class	Reports with this term	Share of class reports	Median drug in class
Atypical antipsychotic	1,430	0.2%	0.2%
Opioid agonist	849	0.1%	0%
Serotonin reuptake inhibitor	587	0.2%	0.1%
Serotonin and norepinephrine reuptake inhibitor	293	0.2%	0.1%
Leukotriene receptor antagonist	247	0.6%	0.6%
Benzodiazepine	223	0.1%	0%
Anti-epileptic agent	221	0.1%	0%
Central nervous system stimulant	184	0.2%	0%
HMG-CoA reductase inhibitor	150	0.1%	0%
Partial cholinergic nicotinic agonist	145	0.2%	0.3%

Classes ordered by count. Class shares follow the class's overall report volume as much as anything else.

Patients in these reports

Patient age

Under 20.5%27

2 to 116%344

12 to 176.1%346

18 to 4425.3%1,442

45 to 6421.3%1,213

65 to 746.5%368

75 and over4%227

Age not given30.4%1,731

Patient sex

Female50.6%2,884

Male43.2%2,464

Not given6.1%350

Grey bar: all 20,646,523 reports in the database. 48.5% of these reports give the United States as the country.

Questions about "Social avoidant behaviour"

What does "Social avoidant behaviour" mean in an adverse event report?

It is a MedDRA preferred term, the dictionary FDA uses to code what a reporter described. The report's own description is not published by openFDA and is not shown here.

How many reports record social avoidant behaviour?

5,698 reports through June 2026 (0% of all reports), 178 of them in the latest 12 months.

Which drugs appear most often in these reports?

Novothyrox (401), Olanzapine (185), Aripiprazole (184), OxyContin (176) and Oxycodone hydrochloride (172). Drugs with many reports overall lead almost every term's list. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Does a drug appearing here mean it was responsible for this reaction?

No. FDA states that "a causal relationship cannot be established between product and reactions listed in a report" and that for any given report "there is no certainty that a suspected drug caused the event."

I have this symptom. What should I do?

This site cannot assess anyone. A pharmacist or clinician can; for an emergency, call the local emergency number. Nothing on this page is medical advice.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. Terms are pooled across spelling and capitalisation variants of one MedDRA preferred term. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.